Greenphire talks clinical trial challenges at DIA Global Annual Meeting

Greenphire, a company centered on financial lifecycle management technology for clinical studies, discussed its range of offerings aimed at helping clinical research operations better streamline their studies. For example, its EnvisiX technology, first launched two years ago, is intended to streamline the budgeting process via access to up-to-date, fair-market-value data for clinical trials around the globe; according to the company, contract research organizations (CROs) in North America, Europe, Latin America, and Asia, have seen improvements in workflow, collaboration, and transparency.

Linical (a full-spectrum, multinational CRO) was among EnvisiX’s early adopters. Clareece West, executive vice president for commercial operations at Linical, said, “We are excited to partner with Greenphire, enabling access to the most robust and contemporary investigator grant negotiated actuals data in the industry. This data, along with the ease of building a budget through a simple and flexible tool, brings considerable value to our clients’ clinical development programs​."

Ashley Baxter, Greenphire’s clinical pricing analyst, presented a session at DIA, “Optimizing Study Budgeting and Access to Industry Indicative FMV Data to Accelerate Trial Timelines​” on June 22.

Regardless of study size or resources of the sponsor initiating a study, building and negotiating an appropriate budget continues to be one of the most complex, time-consuming, and costly aspects of a clinical trial​,” Baxter said. “I am honored to share how tools like Greenphire’s EnvisiX, are able to optimize and simplify the process through an intuitive workflow and access to real-time FMV data.​”

 ​